Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.58 |
| ▸ | CA6 | P23280 | 5/20 | 0.58 |
| ▸ | CA7 | P43166 | 5/20 | 0.58 |
| ▸ | CA9 | Q16790 | 5/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.58 |
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA4 | P22748 | 4/20 | 0.58 |
| ▸ | CA5A | P35218 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CA3 | P07451 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27610245 | 0.92 | CA12 (0.69) | CA12CA6CA7CA9CA14 | |
| SCHEMBL14782398 | 0.92 | — | — | |
| SCHEMBL3343779 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL6483185 | 0.86 | CA12 (0.61) | CA12CA6CA7CA9CA14 | |
| SCHEMBL3221877 | 0.86 | CA12 (0.71) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL13685489 | 0.76 | CA12 (0.85) | CA12CA6CA7CA9CA14 | |
| SCHEMBL25342018 | 0.76 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL15439 | 0.76 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL10917234 | 0.76 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL25340653 | 0.76 | CA12 (1.00) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677775-B1 | THERAPEUTIC USE OF METHIONINE FOR THE TREATMENT OR PREVENTION OF MUCOSITIS | UNIV SOUTHERN ILLINOIS (US) | 2011-12-07 | — | — | EP | claimed |
| US-20050281892-A1 | Highly efficacious and highly safe composition of a Stilbene derivative and a platinum coordination compound cis-diaminedichloroplatinum (II) | AJINOMOTO CO., INC. (JP) | 2005-12-22 | — | — | US | claimed |
| US-20050101534-A1 | Compositions and methods for treating or preventing hearing impairment | SEPRACOR, INC. (US) | 2005-05-12 | — | — | US | claimed |
| WO-2004043447-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEARING IMPAIRMENT | SEPRACOR, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| EP-1393729-A2 | Combination chemotherapy involving topotecan and a platinum coordination compound | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-03 | — | — | EP | claimed |
| EP-1393730-A2 | Combination chemotherapy involving topotecan and a platinum coordination compound | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-03 | — | — | EP | claimed |
| US-6630124-B1 | Polypeptide which is an antagonist of the vasoactive intestinal polypeptide and a chemotherapeutic agent | RAMOT-UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2003-10-07 | — | — | US | claimed |
| EP-1126871-A2 | COMBINATION THERAPY WITH VIP ANTAGONIST | The Government of The United States of America, as represented by The Department of Health and Human Services (US) | 2001-08-29 | — | — | EP | claimed |
| US-6187817-B1 | PREVENTING OR REDUCING OTOTOXICITY IN A HUMAN, CAT OR DOG BY ADMINISTERING D-METHIONINE FREE OF THE L-ISOMER | SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE | 2001-02-13 | — | — | US | claimed |
| WO-2000023096-A2 | COMBINATION THERAPY WITH VIP ANTAGONIST | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-04-27 | — | — | WO | claimed |
| EP-3849558-B1 | THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS | iTeos Belgium SA (BE) | 2024-06-05 | — | — | EP | disclosed |
| US-20240141436-A1 | Compounds, Compositions and Methods of Treatment Thereof | iTeos Belgium SA (BE) | 2024-05-02 | — | — | US | disclosed |
| WO-2024040036-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF DISEASE ASSOCIATED WITH EXPRESSION OF AT LEAST ONE ANTIBODY-SECRETING CELL MARKER | iTeos Belgium SA (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20240025961-A1 | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 | THE UNIVERSITY OF CHICAGO (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4294948-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT THEREOF | iTeos Belgium SA (BE) | 2023-12-27 | — | — | EP | disclosed |
| US-5633016-A | ADMINISTERING CISPLATIN AND TOPOTECAN SYNERGISTIC MIXTURE AS ANTITUMOR AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| EP-0612248-A4 | COMBINATION CHEMOTHERAPY. | SMITHKLINE BEECHAM CORP (US) | 1996-05-08 | — | — | EP | disclosed |
| EP-0612248-A1 | COMBINATION CHEMOTHERAPY | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993009782-A1 | COMBINATION CHEMOTHERAPY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-27 | — | — | WO | disclosed |
| US-5002755-A | Administering A Dithiocarbamate Chelator | VANDERBILT UNIVERSITY (US) | 1991-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240141436-A1 | Compounds, Compositions and Methods of Treatment Thereof | ADORA2A, ADORA2B, ADORA3 | CA12 2088/4885CA6 2592/4885CA7 3410/4885 |
| US-20050281892-A1 | Highly efficacious and highly safe composition of a Stilbene derivative and a platinum coordination compound cis-diaminedichloroplatinum (II) | MSH2, TOP2B, TP53 | CA12 205/4885CA6 1258/4885CA7 946/4885 |
| US-20050101534-A1 | Compositions and methods for treating or preventing hearing impairment | OTC, MSH2, OAT | CA12 377/4885CA6 843/4885CA7 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.